Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer

被引:10
|
作者
Gupta, Swati [1 ]
Mani, Navin R. [1 ]
Carvajal-Hausdorf, Daniel E. [1 ,2 ]
Bossuyt, Veerle [1 ]
Ho, Kenneth [3 ]
Weidler, Jodi [4 ]
Wong, Wendy [3 ]
Rhees, Brian [3 ]
Bates, Michael [4 ]
Rimm, David L. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA
[2] Univ Desarrollo, Fac Med, Clin Alemana, Anat Patol, Santiago, Chile
[3] Cepheid, Div Oncol Res & Dev, Oncol, Sunnyvale, CA USA
[4] Cepheid, Med & Sci Affairs & Strategy, Oncol, Sunnyvale, CA USA
关键词
MESSENGER-RNA; IN-SITU; IMMUNOHISTOCHEMISTRY; CARCINOMA; TAMOXIFEN; ASSAY;
D O I
10.1038/s41374-018-0064-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
An on-demand, closed RT-qPCR, the GeneXpert (GX) system, has the potential to provide biomarker information in low-resourced settings and elsewhere. We used this system with a research use only version of the Breast Cancer STRAT4 cartridge that measures the mRNA expression levels of ERBB2, ESR1, PGR, and MKi67. Here we evaluated the impact of non-macrodissected (non m-d) versus macrodissected (m-d) samples using STRAT4 on formalin-fixed, paraffin-embedded (FFPE) core needle biopsies. Two cohorts were assessed: (1) 60 FFPE infiltrating ductal carcinoma (IDCA) cases and (2) 20 FFPE IDCA cases with ductal carcinoma in situ (DCIS) with a range of HER2 expression as determined by clinical immunohistochemistry and fluorescence in situ hybridization (IHC/FISH). We observed about half of the core needle biopsy area as invasive tumor in both IDCA (mean = 51.5%) and IDCA with DCIS (mean = 53.5%) cohorts, but also found the mRNA levels were independent of tumor area. We found excellent agreement of the mRNA transcript level between the paired samples, m-d versus non m-d, for ERBB2, ESR1, PGR, and MKi67 for both the IDCA and IDCA with DCIS cohorts. No significant difference (P > 0.99) was observed when we compared the mRNA transcript level between the paired samples m-d versus non m-d. In addition, we noted a significant concordance (P < 0.001) between RT-qPCR and IHC/FISH for HER2-positivity, ER-positivity, and PR-positivity, independent of specimen dissection. These data suggest that mRNA expression for ERBB2, ESR, and PGR is sufficiently low in surrounding tissue cells such that macrodissection is not required for assessment of key breast cancer mRNA markers and is independent of the amount of input tumor. This approach may be valuable in settings lacking pathology expertise or using specimen types, such as fine-needle aspirates, where it may be challenging to separate non-tumor from tumor tissue.
引用
收藏
页码:1076 / 1083
页数:8
相关论文
共 50 条
  • [21] Clinical utility of RT-PCR in assessing HER 2 gene expression versus traditional IHC and FISH in breast cancer patients
    Suryavanshi, Moushumi
    Mehta, Anurag
    Jaipuria, Jiten
    Kumar, Dushyant
    Vishwakarma, Gayatri
    Panigrahi, Manoj Kumar
    Verma, Haristuti
    Saifi, Mumtaz
    Sharma, Sanjeev
    Tandon, Simran
    Doval, D. C.
    Das, Bhudev C.
    BREAST CANCER, 2018, 25 (04) : 416 - 430
  • [22] Estrogen receptor positive operable breast cancer: Does menopausal status impact on HER2 and progesterone receptor status?
    Wang, Ning
    Wang, Bin
    Wang, Yajie
    Hu, Jia
    BREAST, 2011, 20 (06) : 519 - 524
  • [23] Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer
    Chen, Xiao-song
    Ma, Chuan-dong
    Wu, Jia-yi
    Yang, Wen-tao
    Lu, Hong-fen
    Wu, Jiong
    Lu, Jin-song
    Shao, Zhi-min
    Shen, Zhen-zhou
    Shen, Kun-wei
    TUMORI JOURNAL, 2010, 96 (01): : 103 - 110
  • [24] EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS
    Shen, Jun
    Wang, Lin-bo
    Teng, Rong-yue
    Shen, Jian-guo
    ACTA MEDICA MEDITERRANEA, 2022, 38 (03): : 1595 - 1600
  • [25] Reckoning the Status of HER2/neu Protein and Oncogene in Breast Cancer Specimens: Comparison of IHC Assay with FISH Assay at a Tertiary Care Centre, West India
    Solanki, Ranjana
    Saini, Sarla
    Sharma, Utkarsh
    Shihora, Nidhi, V
    Maan, Pratibha
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2023, 17 (04) : EC23 - EC27
  • [26] The Effect of Prolonged Fixation on the Immunohistochemical Evaluation of Estrogen Receptor, Progesterone Receptor, and HER2 Expression in Invasive Breast Cancer: A Prospective Study
    Tong, Leung Chu
    Nelson, Nahid
    Tsourigiannis, Jim
    Mulligan, Anna Marie
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2011, 35 (04) : 545 - 552
  • [27] Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status
    Garrison, Louis P., Jr.
    Lalla, Deepa
    Brammer, Melissa
    Babigumira, Joseph B.
    Wang, Bruce
    Perez, Edith A.
    CANCER, 2013, 119 (17) : 3113 - 3122
  • [28] Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells
    Patki, Mugdha
    Salazar, Marcela d'Alincourt
    Trumbly, Robert
    Ratnam, Manohar
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 457 (03) : 404 - 411
  • [29] Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies
    Nayar, Utthara
    Cohen, Ofir
    Kapstad, Christian
    Cuoco, Michael S.
    Waks, Adrienne G.
    Wander, Seth A.
    Painter, Corrie
    Freeman, Samuel
    Persky, Nicole S.
    Marini, Lori
    Helvie, Karla
    Oliver, Nelly
    Rozenblatt-Rosen, Orit
    Ma, Cynthia X.
    Regev, Aviv
    Winer, Eric P.
    Lin, Nancy U.
    Wagle, Nikhil
    NATURE GENETICS, 2019, 51 (02) : 207 - +
  • [30] Expression of wild-type estrogen receptor β protein in human breast cancer:: Specific correlation with HER2/neu overexpression
    Umekita, Yoshihisa
    Souda, Masakazu
    Ohi, Yasuyo
    Sagara, Yoshiatsu
    Rai, Yoshiaki
    Takahama, Tetsuya
    Yoshida, Hiroki
    PATHOLOGY INTERNATIONAL, 2006, 56 (08) : 423 - 427